The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical Use of Continuous Glucose Monitoring in Adults with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Hemoglobin A1c is an excellent population health measure for the risk of vascular complications in diabetes, while continuous glucose monitoring (CGM) is a tool to help personalize a diabetes treatment plan. The value of CGM in individuals with type 1 diabetes (T1D) has been well demonstrated when compared with utilizing self-monitoring of blood glucose (SMBG) to guide treatment decisions. CGM is a tool for patients and clinicians to visualize the important role that diet, exercise, stress management, and the appropriate selection of diabetes medications can have in managing type 2 diabetes (T2D). Several diabetes organizations have recently reviewed the literature on the appropriate use of CGM in diabetes management and concluded CGM may be a useful educational and management tool particularly for patients on insulin therapy. The indications for using CGM either as a clinic-based loaner distribution model for intermittent use (professional CGM) or a CGM system owned by the patient and used at home with real-time glucose reading (personal CGM) are only beginning to be addressed in T2D. Most summaries of CGM studies conclude that having a standardized glucose pattern report, such as the ambulatory glucose profile (AGP) report, should help facilitate effective shared decision-making sessions. The future of CGM indications for the use of CGM is evolving rapidly. In some instances, CGM is now approved for making medication adjustments without SMBG confirmation and it appears that some forms of CGM will be approved for use in the Medicare population in the United States in the near future. Many individuals with T1D and T2D and their care teams will come to depend on CGM as a key tool for diabetes management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 2×
“There is also a role for CGM use in special populations as well as clinical research, which has been reviewed elsewhere.(2)”
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“The Daily Injections and Continuous Glucose Monitoring in Diabetes (DIaMonD) study is a 6-month randomized control trial comparing the effectiveness of using RT-CGM versus SMBG to optimize glycemic control in individuals with T1D and T2D using multiple daily injections.(14,15) The data from the T1D cohort of the DIAMO…”
Self-citationHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 1×
“conducted a randomized controlled trial that looked at 224 patients on intensive insulin therapy (prandial and basal insulin, prandial only, or insulin pump therapy) for T2D randomized to use the personal flash CGM (using the Abbott FreeStyle Libre system, Abbott Diabetes Care, Witney, United Kingdom) versus SMBG over…”
Aleppo, G., Ruedy, K. J., Riddlesworth, T. D., Kruger, D. F., Peters, A. L., Hirsch, I., Bergenstal, R. M., Toschi, E., Ahmann, A. J., Shah, V. N., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2482 · Cited by 329
Self-citationBergenstal, R. M., Ahmann, A. J., Bailey, T., Beck, R. W., Bissen, J., Buckingham, B., Deeb, L., Dolin, R. H., Garg, S. K., Goland, R., et al. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0051 · Cited by 307
Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review
Rushforth, B., McCrorie, C., Glidewell, L., Midgley, E., & Foy, R. (2016) · British Journal of General Practice · doi:10.3399/bjgp16x683509 · Cited by 289 · cited 1×
“Most diabetes P4P agreements are focused on measures of HbA1c, blood pressure, LDL cholesterol, tobacco cessation, and aspirin use for their entire patient population with diabetes.(54,55) These population health measures are meant to reflect good quality diabetes care of a population of patients, but what happens at…”
Peters, A. L., Ahmann, A. J., Battelino, T., Evert, A., Hirsch, I. B., Murad, M. H., Winter, W. E., & Wolpert, H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2534 · Cited by 250 · cited 1×
“The Endocrine Society recommends short-term, intermittent RT-CGM use in adult patients with T2D (not on prandial insulin) who have HbA1c levels ‡7% and are willing and able to use the device.(49) The results of the aforementioned DIAMOND study may lend evidence to support the use of RT-CGM in T2D patients Table 1.”
Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.06.015 · Cited by 244 · cited 1×
“Similar improvements in HbA1c with intermittent RT-CGM use in T2D have been seen in other studies.(11) Poolsup et al.”
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199 · cited 1×
“The 12-week intervention was followed by a 40week follow-up.(7) They showed a decrease in the RT-CGM group’s mean unadjusted HbA1c of 1.”
Fonseca, V. A., Grunberger, G., Anhalt, H., Bailey, T. S., Blevins, T., Garg, S. K., Handelsman, Y., Hirsch, I. B., Orzeck, E. A., Roberts, V. L., et al. (2016) · Endocrine Practice · doi:10.4158/ep161392.cs · Cited by 195
Cited by
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Self-citationInternational consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
“There are limited data regarding the benefit of rtCGM as an outcome measure for individuals with gestational diabetes mellitus and type 2 diabetes, especially for those who do not use insulin (48) [C].”
BackgroundSelf-citationMaiorino, M. I., Signoriello, S., Maio, A., Chiodini, P., Bellastella, G., Scappaticcio, L., Longo, M., Giugliano, D., & Esposito, K. (2020) · Diabetes Care · doi:10.2337/dc19-1459 · Cited by 364
Lee, I., Probst, D., Klonoff, D., & Sode, K. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113054 · Cited by 288
Alva, S., Bailey, T., Brazg, R., Budiman, E. S., Castorino, K., Christiansen, M. P., Forlenza, G., Kipnes, M., Liljenquist, D. R., & Liu, H. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820958754 · Cited by 164
Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
“Despite numerous advances in therapeutics, many of the patients with T2D are not able to achieve glycemic control.8 This may be due to relatively less use of diabetes technology in patients with T2D compared to patients with T1D.”
BackgroundGarcía‐Moreno, R. M., Benítez‐Valderrama, P., Barquiel, B., González Pérez‐de‐Villar, N., Hillman, N., Lora Pablos, D., & Herranz, L. (2022) · Diabetic Medicine · doi:10.1111/dme.14703 · Cited by 100
Continuous glucose monitoring: Current use in diabetes management and possible future applications
Vettoretti, M., Cappon, G., Acciaroli, G., Facchinetti, A., & Sparacino, G. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818774078 · Cited by 96
Bergenstal, R. M., Mullen, D. M., Strock, E., Johnson, M. L., & Xi, M. X. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108106 · Cited by 87
Self-citationImproved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63
The History, Evolution and Future of Continuous Glucose Monitoring (CGM)
Bender, C., Vestergaard, P., & Cichosz, S. L. (2025) · Diabetology · doi:10.3390/diabetology6030017 · Cited by 43
Significance of Glycemic Variability in Diabetes Mellitus
Kusunoki, Y., Konishi, K., Tsunoda, T., & Koyama, H. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8424-21 · Cited by 40
Rivera-Ávila, D. A., Esquivel-Lu, A. I., Salazar-Lozano, C. R., Jones, K., & Doubova, S. V. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00742-5 · Cited by 32
Hirsch, I. B., & Verderese, C. A. (2017) · Endocrine Practice · doi:10.4158/ep171962.ra · Cited by 22
Artificial intelligence in diabetes management
Thomas, A., Gopi, V. P., & Francis, B. (2024) · Advances in Artificial Intelligence · doi:10.1016/b978-0-443-19073-5.00002-1 · Cited by 3
Metadata
- Authors
- Carlson, A. L., Mullen, D. M., & Bergenstal, R. M.
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2017-05
- Volume
- 19
- Issue
- S2
- Pages
- S-4-S-11
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2618217557
- Cited by
- 177
- References
- 18
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.